Menogaril

Drug Profile

Menogaril

Alternative Names: 7 OMEN; Menogarol; NSC 269148; Tomosar; TUT 7; U 52047; UT 7

Latest Information Update: 04 Jul 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Anthracyclines; Cytostatic antibiotics; Nogalamucins
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Breast cancer; Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Multiple myeloma; Myeloid leukaemia; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Discontinued Lymphoma

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-I for Cancer in Canada (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Breast cancer in European Union (unspecified route)
  • 04 Jul 2006 No development reported - Phase-II for Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top